We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

MP BIOMEDICALS LLC

MP Biomedicals manufactures and sells a comprehensive line of in-vitro diagnostics solutions to hospitals and clinica... read more Featured Products: More products

Download Mobile App





MP Biomedicals Exhibits Innovative POC, Screening and Confirmatory Tests at MEDICA 2022

By LabMedica International staff writers
Posted on 15 Nov 2022
Print article
Image: The MP Biomedicals team at MEDICA 2022 (Photo courtesy of MP Biomedicals)
Image: The MP Biomedicals team at MEDICA 2022 (Photo courtesy of MP Biomedicals)

MP Biomedicals (Eschwege, Germany) is exhibiting its wide product portfolio of POC, screening and confirmatory tests, backed by a range of testing methods that aid in the diagnosis, detection, and recovery from diseases, at MEDICA 2022.

At this year’s edition of MEDICA, MP Biomedicals is exhibiting the AutoBlot System 36, an intelligent Western Blot processor that enables automated washing and incubation of up to 36 assay strips per run at a pre-selected temperature. The AutoBlot System 36 helps to satisfy Immunoblot needs by minimizing human error, increasing productivity and delivering accurate and consistent results. MP Biomedicals is also showcasing its innovative diagnostic tests such as the Rapid SARS-CoV-2 Antigen Test Card, an IVD test for private use to detect SARS-CoV-2 antigens from anterior nasal swabs, alongside the Rapid 2019-nCoV IgG/IgM Combo Test Card, which is an immunochromatography based one-step in vitro test designed for the rapid qualitative determination of IgG and IgM antibodies to 2019 novel coronavirus (2019-nCoV,SARS-CoV-2) in human serum, plasma, or whole blood.

MP Biomedicals is also highlighting its POC testing and screening solutions for the qualitative assessment of drugs and their metabolites in human urine and saliva. Visitors to the MP Biomedicals booth at MEDICA 2022 can gain insights into the MP Diagnostics HIV BLOT 2.2 qualitative enzyme immunoassay for the in vitro detection of antibodies to human immunodeficiency virus type 1 (HIV-1) and type 2 (HIV-2) in human serum or plasma. HIV BLOT 2.2 is intended for use as a more specific supplemental test on human serum or plasma specimens found repeatedly reactive using screening procedures such as the Enzyme-Linked Immunosorbent Assay (ELISA). Also on display at the event is the MP Diagnostics MULTISURE HIV 1/2 Confirmatory Test for use as a rapid confirmatory test to detect and differentiate antibodies specific to HIV-1 gp120, HIV-1 gp41, HIV-1 p24 and HIV-2 gp36, HIV-2 gp105 antigens in human serum or plasma.

Related Links:
MP Biomedicals

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.